Royal Bank Of Canada Aim Immuno Tech Inc. Transaction History

Royal Bank Of Canada

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $0.61 $0 - $0	-1 Reduced 0.56%	179 $0
Q1 2024 Nov 05, 2024	BUY	$0.33 - $0.48 $0 - $0	1 Added 0.56%	180 $0
Q1 2024 May 15, 2024	BUY	$0.33 - $0.48 $0 - $0	1 Added 0.56%	180 $0
Q4 2023 Feb 14, 2024	SELL	$0.4 - $0.56 $48 - $68	-122 Reduced 40.53%	179 $0
Q3 2023 Nov 14, 2023	SELL	$0.44 - $0.71 $3 - $4	-7 Reduced 2.27%	301 $0
Q2 2023 Aug 14, 2023	BUY	$0.4 - $0.67 $119 - $199	298 Added 2980.0%	308 $0
Q1 2023 May 15, 2023	BUY	$0.32 - $0.77 $1 - $3	4 Added 66.67%	10 $0
Q4 2022 Feb 14, 2023	SELL	$0.31 - $0.6 $135 - $262	-437 Reduced 98.65%	6 $0
Q3 2022 Nov 14, 2022	BUY	$0.57 - $0.81 $252 - $358	443 New	443 $0
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.27 $0 - $1	-1 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.92 - $1.96 $0 - $1	1 New	1 $0
Q3 2021 Nov 15, 2021	SELL	$1.91 - $2.17 $26 - $30	-14 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.93 - $2.39 $27 - $33	14 New	14 $0

9.01M

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $10.1M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.